The effect of oral medium chain triglycerides in healthy individuals

Completed

Conditions: 10013317
but a follow-up study will include Very Long Chain Acetyl-CoA Dehydrogenase deficiency (a fatty acid oxidation disorder)
In this study only healthy subjects

Registration Number: NL-OMON46931

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 6

Inclusion Criteria

- Healthy male
- Age 18+
- BMI 18-25 kg/m2

Exclusion Criteria

Dyslipidemia (hypertriglyceridemia)
Any acute or chronic illness that would interfere with the subjects safety and ability to comply with protocol requirements

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Actual study:<br /><br>- 13C enrichment of breath CO2.<br /><br>- 13C enrichment of C12-22 of plasma fatty acids in plasma: triglycerides (TG),<br /><br>phospholipids (PL), Cholesterol esters (CE), VLDL, LDL, HDL and free fatty<br /><br>acids (FA)<br /><br><br /><br>Pilot:<br /><br>* Establish minimum duration of fasting that enables us to detect appropriate<br /><br>levels of LCT and free fatty acids in plasma.<br /><br>* Establish duration of oral MCT administration to accurately measure<br /><br>enrichment in plasma fatty acids and breath CO2.<br /><br>* Establish if one week of wash-out period is sufficient to clear MCT-tracer<br /><br>from plasma.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>* Resting energy expenditure<br /><br><br /><br>Pilot<br /><br>* Response of plasma metabolites (glucose, pyruvate, lactate, ketones,<br /><br>triglycerides, free fatty acids, insulin, cortisol, acylcarnitines, amino<br /><br>acids) to 36 hours of fasting</p><br>